Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 2:07 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1633–1656 of 14,141 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Safety Control Clear all

Conditions: Non-Cirrhotic Non-alcoholic Steatohepatitis With Fibrosis
Interventions: AZD4831, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 17
States / cities: Chandler, Arizona • Tucson, Arizona • Chula Vista, California + 13 more

Conditions: Injury of Ureter During Surgery (Disorder)
Interventions: Nizaracianine Triflutate, Placebo Comparator; Drug
Lead sponsor: Curadel Surgical Innovations, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 5
States / cities: Los Angeles, California • Redwood City, California • Orlando, Florida + 2 more

Conditions: Obesity, Overweight
Interventions: LY4174794, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 116 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: San Antonio, Texas • Salt Lake City, Utah

Conditions: Lupus Nephritis
Interventions: Atacicept, Mycophenolate mofetil, Placebo, Corticosteroids; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 16 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 12
States / cities: New Orleans, Louisiana • Shreveport, Louisiana • Detroit, Michigan + 9 more

Conditions: Central Abdominal Bulging
Interventions: LIPO-202, Placebo; Drug
Lead sponsor: Neothetics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2015
U.S. locations: 6
States / cities: Encinitas, California • Manhattan Beach, California • Aventura, Florida + 3 more

Conditions: Medication Compliance
Interventions: Pharmacist-led medication therapy using mHealth application; Other
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Open-Label, Placebo Comparator: Placebo-Control Arm 0.9% Sodium Chloride, ODSH; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 10
States / cities: Orange, California • Marietta, Georgia • Shreveport, Louisiana + 6 more

Conditions: Hypertension
Interventions: Nebivolol, Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 54 Years
Enrollment: 641 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 75
States / cities: Phoenix, Arizona • Buena Park, California • Burbank, California + 58 more

Conditions: Bronchiectasis
Interventions: Inhaled mannitol, Matched control; Drug
Lead sponsor: Syntara; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 485 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 19
States / cities: Denver, Colorado • Farmington, Connecticut • Washington D.C., District of Columbia + 15 more

Conditions: Healthy Participants
Interventions: AZD2389, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Glendale, California

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Canakinumab, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 11
States / cities: Anaheim, California • Los Angeles, California • Panama City, Florida + 8 more

Conditions: Diabetes Mellitus, Type 2
Interventions: albiglutide, sitagliptin; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 507 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 121
States / cities: Birmingham, Alabama • Gulf Shores, Alabama • Huntsville, Alabama + 97 more

Conditions: Healthy Volunteer
Interventions: AZD7268, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Systemic Lupus Erythematosus
Interventions: AMG 570, AMG 570 Matching Placebo; Biological
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 3
States / cities: Evansville, Indiana • Overland Park, Kansas • Madison, Wisconsin

Conditions: Type 2 Diabetes Mellitus
Interventions: KD026, Placebo, Metformin; Drug
Lead sponsor: Response Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 10
States / cities: Birmingham, Alabama • Los Angeles, California • West Hills, California + 6 more

Conditions: Chronic Osteoarthritis Pain, Chronic Low Back Pain
Interventions: PIPE-791, Placebo; Drug
Lead sponsor: Contineum Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 5
States / cities: Phoenix, Arizona • Marietta, Georgia • Hartsdale, New York + 2 more

Conditions: Schizophrenia
Interventions: Luvadaxistat, Placebo; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 16
States / cities: Garden Grove, California • Lemon Grove, California • Los Angeles, California + 13 more

Conditions: Bacterial Infection
Interventions: Ertapenem, Placebo, WCK 6777, Zidebactam; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Diabetes Mellitus, Type 2, Renal Insufficiency
Interventions: BI 10773, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 741 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 18
States / cities: Anaheim, California • Lomita, California • Plantation, Florida + 15 more

Conditions: Hypogonadal Males
Interventions: ABT-SLV361, placebo; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years to 80 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Fort Myers, Florida

Conditions: Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis, Psoriatic Arthritis
Interventions: Bimekizumab, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 435 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 20
States / cities: San Diego, California • Santa Monica, California • Fort Myers, Florida + 15 more

Conditions: Osteoarthritis
Interventions: AGG-523 (Aggrecanase Inhibitor); Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 55 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 5
States / cities: Boston, Massachusetts • Newton, Massachusetts • Winchester, Massachusetts + 1 more

Conditions: Nasal Polyposis
Interventions: Benralizumab 30 mg SC + Mometasone Furoate, Matching placebo SC + Mometasone Furoate; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 413 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 48
States / cities: Birmingham, Alabama • Fresno, California • Huntington Beach, California + 37 more

Conditions: Gout
Interventions: Pegloticase, methotrexate, placebo, folic acid, gout flare prophylaxis regimen, fexofenadine, acetaminophen, methylprednisolone; Biological · Drug · Dietary Supplement
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 60
States / cities: Birmingham, Alabama • Anchorage, Alaska • Flagstaff, Arizona + 54 more

Search by objective public record fields.

A Study in Participants With Non-cirrhotic NASH With Fibrosis

Trial to Visualize the Ureters With Nizaracianine Triflutate in Adults Undergoing Abdominopelvic Surgery

A Study of LY4174794 in Participants With Obesity or Overweight Who Are Otherwise Healthy

The Efficacy and Safety of Atacicept in Combination With Mycophenolate Mofetil Used to Treat Lupus Nephritis

Safety and Efficacy Study of LIPO-202 for the Reduction of Central Abdominal Bulging in Obese Subjects

mHealth Medication Safety Intervention

A Study Designed to Evaluate ODSH in Subjects With Exacerbations of COPD

Study of the Efficacy and Safety of Nebivolol in Younger Patients (18 - 54 Years)

Inhaled Mannitol as a Mucoactive Therapy for Bronchiectasis

A Single and Multiple Ascending Dose Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD2389 in Healthy Participants

Safety and Efficacy of Multiple Doses of Canakinumab (ACZ885) in Chronic Obstructive Pulmonary Disease (COPD) Patients

A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment.

Safety, Tolerability, and Pharmacokinetics of AZD7268 After Single Ascending Oral Doses in Healthy Subjects

Single Ascending Dose Study of AMG 570 in Healthy Subjects

Study of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus

Study of PIPE-791 for Subjects With Chronic Osteoarthritis Pain or Chronic Low Back Pain

A Study to Evaluate 3 Dose Levels of Luvadaxistat of Adults With Negative Symptoms of Schizophrenia

Safety Study of Intravenous Ertapenem in Combination With Zidebactam (WCK 6777)

Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment

Study of the Safety, Tolerability and Pharmacokinetics of Testosterone Undecanoate in Hypogonadal Males.

A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

Study Evaluating AGG-523 in Subjects With Severe Osteoarthritis Requiring Total Knee Replacement

Efficacy and Safety Study of Benralizumab for Patients With Severe Nasal Polyposis

Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled Gout